Genentech

CompanyUnited States

Genentech develops 5 assets, the furthest in phase 3 (navitoclax in myelofibrosis). Mostly small molecule and device acting on apoptosis, BCL2 and cellular senescence; based in the United States.

Assets
5
Furthest
Phase 3
Trials
19
Signals
2

Pipeline

5

  • navitoclax

    Bcl-2 family protein inhibitor (BCL2, BCL2L1, BCL2L2) that promotes apoptosis.

    Phase 3Small moleculeApoptosisBCL2myelofibrosischronic lymphocytic leukemia (Phase 2)

  • ranibizumab

    Sustained-release ocular implant formulation of ranibizumab inhibiting VEGF-A

    Phase 3DeviceVEGFAneovascular age-related macular degenerationbranch retinal vein occlusion (Human trials)

  • OpRegen

    Allogeneic stem cell-derived retinal pigment epithelial cell replacement therapy

    Phase 2Cell therapyStem cell maintenancegeographic atrophy

2 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms9
  • Trials117
  • Signals2
  • Integrity notices3
  • Similar companies6

Updated 7 Oct 2026 · 134 sources

Intelligence